Those KEAP1-binding competitors, such as p21 Cip1/WAF1 and BRCA1, were found interacting with NRF2 and thus block the association of KEAP1 with NRF2 [18, 19]
If the review period increases to 4 months and patients receive 4 or more injections within 1 year, instead of 6 or more, the savings are $15 million
To date, 59 scholars have participated, or are participating, in the DDP
But and its a big but under certain fairly common circumstances, production can start to sputter
* Correspondence: Hongying Kuang, [email protected] Disclaimer All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers